LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.


 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.


       sheep

 
0 7   S2 ______MSGGKYVDS
0 4   K5 ___MSGGKYVDSEGH
1 7   K5 ___MSGGKYVDSEGH
2 104   Y6 __MSGGKYVDSEGHL
0 18   S9 SGGKYVDSEGHLyTV
55 873   Y14‑p VDSEGHLyTVPIREQ
0 129   T15 DSEGHLyTVPIREQG
2 113   Y25 IREQGNIYKPNNKAM
1 14   K26 REQGNIYKPNNKAMA
0 1   K26 REQGNIYKPNNKAMA
0 1   K26 REQGNIYKPNNKAMA
1 12   K30 NIYKPNNKAMAEEMN
0 1   K30 NIYKPNNKAMAEEMN
0 63   N37 KAMAEEMNEKQVYDA
1 24   K39 MAEEMNEKQVYDAHT
0 1   K39 MAEEMNEKQVYDAHT
1 83   Y42 EMNEKQVYDAHTKEI
0 6   T46 KQVYDAHTKEIDLVN
1 7   K47 QVYDAHTKEIDLVNR
0 1   K47 QVYDAHTKEIDLVNR
1 5   K57 DLVNRDPKHLNDDVV
0 1   K57 DLVNRDPKHLNDDVV
0 2   K65 HLNDDVVKIDFEDVI
3 0   S80 AEPEGTHSFDGIWKA
1 0   S88 FDGIWKASFTTFTVT
1 0   S168 EAIGKIFSNIRINTQ
1 2   K176 NIRINTQKEI_____
  human

► Hide Isoforms
 
S2‑p ______MsGGkyVDs
K5‑ac ___MsGGkyVDsEGH
K5‑ub ___MsGGkyVDsEGH
Y6‑p __MsGGkyVDsEGHL
S9‑p sGGkyVDsEGHLytV
Y14‑p VDsEGHLytVPIREQ
T15‑p DsEGHLytVPIREQG
Y25‑p IREQGNIykPNNkAM
K26‑ub REQGNIykPNNkAMA
K26 REQGNIyKPNNkAMA
K26‑sm REQGNIykPNNkAMA
K30‑ub NIykPNNkAMADELs
K30 NIykPNNKAMADELs
S37‑p kAMADELsEkQVyDA
K39‑ub MADELsEkQVyDAHt
K39 MADELsEKQVyDAHt
Y42‑p ELsEkQVyDAHtkEI
T46‑p kQVyDAHtkEIDLVN
K47‑ub QVyDAHtkEIDLVNR
K47 QVyDAHtKEIDLVNR
K57‑ub DLVNRDPkHLNDDVV
K57‑ac DLVNRDPkHLNDDVV
K65‑ub HLNDDVVkIDFEDVI
S80‑p AEPEGTHsFDGIWKA
S88 FDGIWKASFTTFTVT
S168‑p EAVGKIFsNVRINLQ
K176‑ub NVRINLQkEI_____
3251 : Phospho-Caveolin-1 (Tyr14) Antibody
  caveolin-1 iso2  
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
S6 __MADELSEKQVYDA
K8 MADELSEKQVYDAHT
K8 MADELSEKQVYDAHT
Y11 ELSEKQVYDAHTKEI
T15 KQVYDAHTKEIDLVN
K16 QVYDAHTKEIDLVNR
K16 QVYDAHTKEIDLVNR
K26 DLVNRDPKHLNDDVV
K26 DLVNRDPKHLNDDVV
K34 HLNDDVVKIDFEDVI
S49 AEPEGTHSFDGIWKA
S57 FDGIWKASFTTFTVT
S137 EAVGKIFSNVRINLQ
K145 NVRINLQKEI_____
  mouse

 
S2‑p ______MsGGkyVDs
K5 ___MsGGKyVDsEGH
K5‑ub ___MsGGkyVDsEGH
Y6‑p __MsGGkyVDsEGHL
S9‑p sGGkyVDsEGHLytV
Y14‑p VDsEGHLytVPIREQ
T15‑p DsEGHLytVPIREQG
Y25‑p IREQGNIykPNNkAM
K26‑ub REQGNIykPNNkAMA
K26 REQGNIyKPNNkAMA
K26 REQGNIyKPNNkAMA
K30‑ub NIykPNNkAMADEVt
K30 NIykPNNKAMADEVt
T37‑p kAMADEVtEkQVyDA
K39‑ub MADEVtEkQVyDAHt
K39 MADEVtEKQVyDAHt
Y42‑p EVtEkQVyDAHtkEI
T46‑p kQVyDAHtkEIDLVN
K47‑ub QVyDAHtkEIDLVNR
K47 QVyDAHtKEIDLVNR
K57‑ub DLVNRDPkHLNDDVV
K57 DLVNRDPKHLNDDVV
K65 HLNDDVVKIDFEDVI
S80 AEPEGTHSFDGIWKA
S88 FDGIWKASFTTFTVT
S168 EAIGKIFSNIRISTQ
K176‑ub NIRISTQkEI_____
3251 : Phospho-Caveolin-1 (Tyr14) Antibody
  rat

 
S2‑p ______MsGGkYVDs
K5‑ac ___MsGGkYVDsEGH
K5 ___MsGGKYVDsEGH
Y6 __MsGGkYVDsEGHL
S9‑p sGGkYVDsEGHLyTV
Y14‑p VDsEGHLyTVPIREQ
T15 DsEGHLyTVPIREQG
Y25 IREQGNIYkPNNkAM
K26 REQGNIYKPNNkAMA
K26‑ac REQGNIYkPNNkAMA
K26 REQGNIYKPNNkAMA
K30 NIYkPNNKAMADEVN
K30‑ac NIYkPNNkAMADEVN
N37 kAMADEVNEkQVYDA
K39 MADEVNEKQVYDAHT
K39‑ac MADEVNEkQVYDAHT
Y42 EVNEkQVYDAHTkEI
T46 kQVYDAHTkEIDLVN
K47 QVYDAHTKEIDLVNR
K47‑ac QVYDAHTkEIDLVNR
K57 DLVNRDPKHLNDDVV
K57 DLVNRDPKHLNDDVV
K65 HLNDDVVKIDFEDVI
S80 AEPEGTHSFDGIWKA
S88 FDGIWKASFTTFTVT
S168 EAIGKIFSNIRISTQ
E176 NIRISTQEEI_____
3251 : Phospho-Caveolin-1 (Tyr14) Antibody
  dog

 
S2 ______MSGGKYVDS
K5 ___MSGGKYVDSEGH
K5 ___MSGGKYVDSEGH
Y6 __MSGGKYVDSEGHL
S9 SGGKYVDSEGHLyTV
Y14‑p VDSEGHLyTVPIREQ
T15 DSEGHLyTVPIREQG
Y25 IREQGNIYKPNNKAM
K26 REQGNIYKPNNKAMA
K26 REQGNIYKPNNKAMA
K26 REQGNIYKPNNKAMA
K30 NIYKPNNKAMAEEMS
K30 NIYKPNNKAMAEEMS
S37 KAMAEEMSEKQVYDA
K39 MAEEMSEKQVYDAHT
K39 MAEEMSEKQVYDAHT
Y42 EMSEKQVYDAHTKEI
T46 KQVYDAHTKEIDLVN
K47 QVYDAHTKEIDLVNR
K47 QVYDAHTKEIDLVNR
K57 DLVNRDPKHLNDDVV
K57 DLVNRDPKHLNDDVV
K65 HLNDDVVKIDFEDVI
S80‑p AEPEGTHsFDGIWKA
S88‑p FDGIWKAsFTTFTVT
S168 EAVGKIFSNIRINMQ
K176 NIRINMQKET_____